reninangiotensin
system
ra
play
key
role
sever
target
organ
heart
blood
vessel
lung
exert
power
control
mainten
homeostasi
system
activ
convers
angiotensinogen
inact
peptid
angiotensin
ang
renin
action
subsequ
ang
cleav
angiotensinconvert
enzym
ace
gener
ang
ii
main
angiotensin
peptid
whose
action
mediat
two
g
proteincoupl
receptor
gpcr
figur
major
physiolog
function
ang
ii
mediat
receptor
patholog
condit
activ
receptor
induc
deleteri
effect
vasoconstrict
fibrosi
cellular
growth
migrat
fluid
retent
hand
ang
ii
bind
receptor
gener
caus
opposit
effect
compar
action
mediat
receptor
recent
propos
addit
aceang
receptor
axi
ra
possess
counter
regulatori
axi
compos
ang
ma
receptor
figur
ang
biolog
activ
compon
ra
bind
ma
induc
mani
benefici
action
vasodilat
antifibrosi
antihypertroph
antiprolif
effect
peptid
produc
mainli
action
approxim
less
affin
ang
ang
ii
therebi
ang
ii
major
substrat
ang
synthesi
fact
convers
ang
ii
ang
import
regul
ra
activ
sinc
ang
induc
opposit
effect
elicit
ang
ii
addit
form
ang
less
effici
hydrolysi
ang
ang
subsequ
ang
format
relev
ra
highlight
success
obtain
therapeut
strategi
base
pharmacolog
inhibit
system
cardiovascular
respiratori
diseas
blockad
ra
ace
inhibitor
acei
receptor
antagonist
arb
improv
outcom
patient
hypertens
acut
myocardi
infarct
chronic
systol
heart
failur
furthermor
base
involv
aceang
axi
respiratori
diseas
crucial
role
lung
ra
metabol
sever
studi
report
contribut
ra
lung
pathophysiolog
importantli
shown
administr
acei
arb
caus
substanti
increas
plasma
ang
level
lead
assumpt
part
clinic
effect
might
mediat
heptapeptid
inde
effect
acei
arb
block
attenu
ma
antagonist
confirm
role
ang
action
compound
benefici
effect
ang
well
like
particip
effect
acei
arb
repres
evid
potenti
ma
axi
therapeut
target
review
focu
recent
find
relat
pathophysiolog
action
ma
axi
cardiovascular
respiratori
system
also
discuss
promis
initi
develop
new
therapeut
strategi
base
axi
treat
patholog
condit
heart
one
import
target
action
ma
axi
heart
express
endothelium
myofibroblast
cardiomyocyt
fibroblast
classic
pharmacotherapeut
agent
use
treat
heart
failur
includ
acei
arb
aldosteron
receptor
blocker
increas
activ
andor
express
indic
import
cardiac
diseas
establish
progress
addit
pharmacolog
genet
transgen
anim
gene
transfer
approach
evidenc
signific
cardiac
patholog
despit
controversi
concern
consequ
defici
gener
evid
indic
protect
role
heart
crackow
colleagu
first
demonstr
genet
ablat
result
sever
bloodpressureindepend
systol
impair
also
disrupt
abl
acceler
cardiac
hypertrophi
shorten
transit
period
heart
failur
respons
pressur
overload
increas
local
ang
ii
recent
demonstr
loss
enhanc
suscept
myocardi
infarct
increas
mortal
infarct
expans
advers
ventricular
remodel
keep
genet
find
pharmacolog
inhibit
exacerb
cardiac
hypertrophi
fibrosi
hypertens
rat
hand
cardiac
overexpress
prevent
hypertensioninduc
cardiac
hypertrophi
fibrosi
spontan
hypertens
rat
shr
angiiinfus
rat
inde
transfect
lentiviru
contain
cdna
recombin
adenoviru
carri
murin
surround
area
infarct
myocardium
protect
patholog
remodel
cardiac
systol
dysfunct
rat
model
myocardi
infarct
effect
associ
decreas
express
ace
ang
ii
increas
express
ang
collect
observ
reveal
effect
play
protect
role
cardiac
structur
function
sinc
discoveri
ang
late
sever
studi
demonstr
import
effect
peptid
heart
presenc
ang
receptor
ma
heart
abil
organ
produc
ang
evid
role
peptid
cardiac
tissu
function
ang
induc
antiarrhythmogen
effect
ischemiareperfus
injuri
rat
well
prevent
atrial
tachycardia
fibril
rat
dog
treatment
ang
improv
coronari
perfus
cardiac
function
rat
myocardi
infarct
ischemiareperfus
injuri
increas
circul
ang
level
transgen
rat
reduc
cardiac
hypertrophi
fibrosi
induc
isoproterenol
administr
effect
appar
independ
chang
blood
pressur
sinc
grobe
colleagu
demonstr
antifibrot
antihypertroph
action
ang
still
observ
angiiinfus
hypertens
rat
local
overexpress
ang
heart
mice
rat
improv
myocardi
contractil
prevent
isoproterenol
hypertensioninduc
cardiac
remodel
altogeth
find
support
direct
effect
ang
heart
evid
role
ang
ma
pathophysiolog
heart
came
experiment
protocol
util
mice
genet
defici
ma
reveal
cardiac
function
impair
ma
knockout
mice
like
due
increas
extracellular
matrix
protein
deposit
heart
profibrot
phenotyp
may
relat
chang
matrix
metalloproteinas
mmp
tissu
inhibitor
metalloproteinas
timp
level
andor
activ
although
elucid
regard
signal
pathway
involv
ma
activ
necessari
mechan
propos
overexpress
ang
heart
rat
caus
improv
handl
cardiomyocyt
increas
express
keep
result
cardiomyocyt
masdefici
mice
present
slower
transient
accompani
lower
atpas
express
sarcoplasm
reticulum
although
acut
ang
treatment
fail
alter
handl
ventricular
myocyt
rat
find
suggest
import
role
ang
ma
longterm
mainten
homeostasi
heart
one
mechan
ang
play
effect
heart
stimul
nitric
oxid
product
inde
demonstr
ang
via
ma
increas
synthesi
mechan
involv
activ
endotheli
synthas
eno
effect
abolish
absent
cardiomyocyt
masdefici
mice
recent
gome
et
al
found
treatment
isol
cardiomyocyt
rat
ang
effici
prevent
angiiinduc
hypertrophi
modul
calcineurinnfat
signal
cascad
effect
block
synthas
inhibit
guanylyl
cyclas
inhibitor
indic
effect
mediat
nocgmp
pathway
also
ang
inhibit
serumstimul
mitogenactiv
protein
kinas
mapk
activ
cardiac
myocyt
prevent
angiimedi
phosphoryl
rho
kinas
heart
dosedepend
manner
line
data
activ
endogen
significantli
reduc
phosphoryl
heart
hypertens
rat
shr
howev
mercur
et
al
report
overexpress
ang
heart
rat
decreas
angiiinduc
phosphoryl
csrc
kinas
wherea
increas
phosphoryl
unaffect
express
transgen
therebi
suggest
select
effect
ang
intracellular
signal
pathway
relat
cardiac
remodel
overal
data
reveal
key
role
ma
axi
pathophysiolog
cardiac
structur
function
activ
axi
might
import
strategi
develop
new
gener
cardiovascular
therapeut
agent
cardiac
dysfunct
patholog
remodel
heart
earli
studi
report
endothelium
major
site
gener
metabol
ang
addit
ang
endotheli
cell
also
express
ma
thu
recogn
ma
axi
present
vascular
endotheli
cell
modul
function
promot
vasorelax
reduct
oxid
stress
antiprolif
effect
vasodilatori
action
ang
report
mani
studi
sever
vascular
bed
prepar
includ
mous
rat
aortic
ring
canin
porcin
coronari
arteri
canin
middl
cerebr
arteri
porcin
piglet
pial
arteriol
felin
mesenter
vascular
bed
rabbit
renal
affer
arteriol
mesenter
microvessel
normotens
hypertens
rat
vascular
ang
action
still
controversi
human
exampl
shown
ang
caus
vasodil
forearm
circul
normotens
subject
patient
essenti
hypertens
studi
unabl
report
signific
effect
ang
vascular
territori
aceitr
patient
ma
receptor
critic
involv
vascular
effect
ang
fact
mani
action
complet
abolish
partial
block
antagonist
importantli
endotheliumdepend
relax
induc
ang
mous
aortic
ring
absent
vessel
deriv
masknockout
mice
howev
studi
shown
ang
also
interact
ace
receptor
suggest
exist
addit
site
interact
ang
inde
silva
et
al
report
evid
presenc
distinct
subtyp
ang
receptor
sensibl
second
ma
antagonist
aorta
spraguedawley
rat
vascular
effect
ang
endothelium
depend
involv
product
vasodil
product
prostanoid
endotheliumderiv
hyperpolar
factor
edhf
pinheiro
cowork
found
ang
promot
increas
releas
mastransfect
chines
hamster
ovari
cho
cell
furthermor
shortterm
infus
ang
improv
endotheli
function
mechan
involv
releas
rat
ma
delet
result
endotheli
dysfunct
associ
unbal
oxid
stress
also
ma
activ
ang
human
endotheli
cell
stimul
eno
phosphorylationactiv
via
aktdepend
pathway
mechan
appear
involv
ang
vascular
action
rok
et
al
shown
ang
inhibit
vasoconstrict
induc
ang
ii
human
intern
mammari
arteri
therebi
suggest
ang
regul
ang
ii
effect
fact
ang
neg
modul
ang
ii
type
receptormedi
activ
csrc
downstream
target
nad
p
h
oxidas
counterregulatori
action
ang
ang
ii
signal
also
observ
cardiomyocyt
vascular
smooth
muscl
cell
fibroblast
addit
interact
ma
bradykinin
bk
type
receptor
may
modul
ang
effect
blood
vessel
inde
demonstr
ang
potenti
vasodil
hypotens
effect
bk
sever
vascular
bed
major
enzym
involv
ang
format
also
crucial
role
vessel
lovren
et
al
demonstr
amelior
endotheli
homeostasi
via
mechan
involv
reduct
reactiv
oxygen
speci
product
note
effect
attenu
moreov
overexpress
vessel
hypertens
rat
result
reduct
arteri
blood
pressur
improv
endotheli
function
associ
increas
circul
ang
level
overal
data
indic
benefici
effect
least
part
mediat
ang
recent
demonstr
activ
endogen
caus
dosedepend
hypotens
effect
normotens
hypertens
rat
also
respons
bk
administr
augment
rat
chronic
treat
xnt
activ
howev
unabl
demonstr
signific
effect
xnt
blood
pressur
respons
administr
ang
ii
losartan
normotens
hypertens
rat
figur
past
year
particip
ma
axi
establish
progress
pulmonari
diseas
becom
evid
inde
import
role
ra
lung
pathophysiolog
side
effect
pulmonari
toxic
induc
acei
rais
interest
evalu
activ
ma
axi
altern
target
treat
pulmonari
patholog
thu
report
benefici
outcom
induc
activ
axi
anim
model
acut
respiratori
distress
syndrom
ard
pulmonari
hypertens
ph
fibrosi
lung
cancer
studi
point
imbal
aceang
ma
axe
ra
might
relev
lung
diseas
take
account
system
hypotens
import
limit
use
acei
arb
pulmonari
patient
therapi
base
ma
axi
emerg
safe
effici
approach
sinc
studi
use
activ
xnt
gene
transfer
shown
strategi
induc
benefici
pulmonari
outcom
without
chang
system
blood
pressur
rat
mice
imai
colleagu
demonstr
role
ard
pathogenesi
found
sever
ard
reach
knockout
mice
phenotyp
revers
doubl
genet
delet
ace
gene
treatment
recombin
human
furthermor
ang
ii
level
relat
sever
lung
injuri
note
wide
express
pulmonari
endothelium
vasculatur
pneumocyt
also
inhibit
increas
ang
ii
level
attenu
arteri
hypoxemia
ph
amelior
distribut
pulmonari
blood
flow
lipopolysaccharideinduc
lung
injuri
piglet
therefor
studi
suggest
suitabl
target
arrest
develop
ard
patient
risk
stimul
ma
axi
success
use
prevent
revers
ph
fibrosi
anim
activ
use
compound
xnt
induct
overexpress
gene
transfer
effici
prevent
importantli
revers
increas
right
systol
ventricular
pressur
rsvp
pulmonari
fibrosi
imbal
ra
inflamm
anim
rat
mice
ph
induc
monocrotalin
mct
rat
pulmonari
fibrosi
caus
bleomycin
treatment
keep
find
ang
gene
transfer
lung
trigger
similar
protect
action
mcttreat
rat
addit
ang
via
ma
prevent
apoptosi
alveolar
epitheli
cell
jun
ntermin
kinas
jnk
activ
induc
bleomycin
involv
ang
ma
ph
evidenc
observ
xnt
effect
block
furthermor
lung
specimen
patient
idiopath
pulmonari
fibrosi
anim
bleomycininduc
pulmonari
fibrosi
report
reduct
mrna
protein
activ
reciproc
increas
ang
ii
level
grow
bodi
studi
focus
relev
ma
axi
pulmonari
cancer
pathophysiolog
protein
express
reduc
nonsmallcel
lung
carcinoma
nsclc
along
increas
ang
ii
level
moreov
overexpress
cultur
lung
cancer
cell
human
lung
cancer
xenograf
inhibit
cell
growth
vascular
endotheli
growth
factora
vegfa
express
induc
ang
ii
gallagh
tallant
evalu
effect
sever
angiotensin
peptid
ang
ang
ii
ang
ang
ang
cancer
cell
growth
ang
show
signific
attenu
dna
synthesi
prolifer
antiprolif
effect
ang
mediat
receptor
ma
inhibit
pathway
neither
blockag
succeed
inhibit
action
ang
keep
data
antiprolif
effect
ang
observ
human
lung
tumor
xenograft
growth
along
mark
decreas
vessel
densiti
mice
mechan
involv
note
nonrandom
phase
clinic
trial
conduct
petti
colleagu
subcutan
inject
ang
administ
patient
advanc
solid
tumor
refractori
standard
therapi
despit
mild
advers
effect
observ
ang
treatment
gener
well
toler
treatmentrel
death
clinic
benefit
observ
patient
altogeth
studi
provid
insight
involv
ma
axi
lung
cancer
benefici
effect
ang
well
known
howev
therapeut
util
peptid
limit
due
unfavor
pharmacokinet
properti
ang
short
halflif
approxim
second
sinc
rapidli
cleav
peptidas
furthermor
ang
degrad
passag
gastrointestin
tract
oral
administr
thu
new
strategi
crucial
make
feasibl
clinic
applic
ang
recent
formul
base
ang
includ
hydroxypropyl
develop
lula
colleagu
cyclodextrin
pharmaceut
tool
use
design
evalu
drug
formul
enhanc
drug
stabil
absorpt
across
biolog
barrier
offer
gastric
protect
amphiphil
charact
cyclodextrin
allow
possibl
format
supramolecular
inclus
complex
stabil
noncoval
interact
varieti
guest
molecul
regard
formul
allow
oral
administr
ang
pharmacokinet
function
studi
show
oral
administr
significantli
increas
plasma
ang
level
promot
antithrombot
effect
blunt
ma
defici
mice
marqu
colleagu
found
chronic
oral
administr
significantli
attenu
heart
function
impair
cardiac
remodel
induc
isoproterenol
treatment
myocardi
infarct
rat
addit
liposom
deliveri
system
repres
altern
method
administ
ang
administr
liposom
contain
ang
rat
led
prolong
hypotens
effect
sever
day
contrast
respons
observ
free
peptid
use
strategi
use
protect
ang
proteolyt
degrad
propos
klusken
cowork
use
abil
prokaryot
cycliz
peptid
synthes
cyclic
ang
deriv
thioetherbridg
ang
present
increas
stabil
homogen
differ
organ
plasma
enhanc
ang
bioavail
rat
furthermor
cycliz
ang
induc
relax
precontract
aorta
ring
rat
block
ang
receptor
antagonist
provid
evid
cycliz
ang
also
interact
ma
ave
first
nonpeptid
synthet
compound
develop
intent
stimul
ma
receptor
compound
mimic
ang
effect
sever
organ
vessel
kidney
heart
similar
ang
ave
induc
vasodil
effect
absent
aortic
ring
masdefici
mice
moreov
effect
aortic
ring
block
two
ang
receptor
antagonist
ave
potenti
acetylcholineinduc
vasodil
consciou
normotens
rat
effect
abolish
lname
similarli
abl
increas
hypotens
effect
bk
normotens
rat
also
block
effect
ferreira
et
al
report
ave
protect
heart
cardiac
dysfunct
remodel
caus
isoproterenol
treatment
myocardi
infarct
rat
mastransfect
cell
ave
induc
releas
blunt
antagonist
data
support
concept
ave
ang
mimet
action
mediat
interact
ma
use
comput
discoveri
platform
predict
novel
natur
occur
peptid
may
activ
gpcr
two
novel
peptid
design
amino
acid
sequenc
unrel
angiotensin
peptid
found
display
high
specif
ma
peptid
elicit
influx
cho
cell
overexpress
ma
without
activ
receptor
deriv
peptid
induc
benefici
cardiovascular
effect
similar
caus
ang
compound
compet
ang
bind
site
mastransfect
cell
furthermor
similar
ang
produc
vasodil
effect
absenc
masdefici
mice
indic
compound
also
act
via
ma
confirm
inhibit
effect
ma
antagonist
importantli
savergnini
et
al
show
promot
antiarrhythmogen
effect
produc
small
dosedepend
decreas
arteri
pressur
consciou
shr
new
approach
address
therapeut
potenti
activ
ma
axi
propos
prada
et
al
base
crystal
structur
use
virtual
screen
strategi
identifi
small
molecul
may
interact
enzym
lead
chang
conform
consequ
enhanc
activ
thu
activ
name
xnt
identifi
administr
shr
decreas
blood
pressur
induc
improv
cardiac
function
revers
myocardi
perivascular
fibrosi
observ
anim
benefici
effect
xnt
also
observ
rat
ph
induc
mct
furthermor
compound
attenu
thrombu
format
reduc
platelet
attach
vessel
hypertens
rat
appear
pharmacolog
activ
promot
benefici
effect
due
increas
ang
product
concomit
degrad
ang
ii
fact
coadministr
abolish
protect
effect
xnt
ph
addit
antifibrot
effect
xnt
observ
heart
shr
associ
increas
cardiac
ang
express
howev
also
pertin
point
offtarget
effect
xnt
benefici
outcom
rule
present
time
complex
ra
far
beyond
could
suspect
year
ago
grow
evid
chang
novel
compon
ra
ang
ma
may
take
part
establish
progress
cardiovascular
respiratori
diseas
importantli
new
compon
ra
due
counter
regulatori
action
candid
serv
concept
develop
new
cardiovascular
respiratori
drug
